![]() We evaluated the safety and feasibility of an anti-EGFR antibody, panitumuab-IRDye800, at subtherapeutic doses as an imaging agent for HGG. The epidermal growth factor receptor (EGFR) is a highly expressed HGG biomarker. The extent of resection predicts overall survival, but current neuroimaging approaches lack tumor specificity. Rationale: First-line therapy for high-grade gliomas (HGGs) includes maximal safe surgical resection. Select the file that you have just downloaded and select import option Reference Manager (RIS). EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial. Zhou Q, van den Berg NS, Rosenthal EL, Iv M, Zhang M, Vega Leonel JCM, Walters S, Nishio N, Granucci M, Raymundo R, Yi G, Vogel H, Cayrol R, Lee YJ, Lu G, Hom M, Kang W, Hayden Gephart M, Recht L, Nagpal S, Thomas R, Patel C, Grant GA, Li G. ✉ Corresponding author: Quan Zhou, PhD, Departments of Neurosurgery and Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, 1201 Welch road MSLS P329, Stanford, CA 94305 Tel: (650)726-6034 Email: qzhedu Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA. Department of Neuropathology, Stanford University School of Medicine, Stanford, CA, USA.ħ. Cancer Clinical Trials Office, Stanford University School of Medicine, Stanford, CA, USA.Ħ. Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.ĥ. Stanford Cancer Center, Stanford University, Stanford, CA, USA.Ĥ. Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.ģ. Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.Ģ. Vega Leonel 1, Shannon Walters 4, Naoki Nishio 2, Monica Granucci 5, Roan Raymundo 2,5, Grace Yi 2,5, Hannes Vogel 6, Romain Cayrol 6, Yu-Jin Lee 2, Guolan Lu 2, Marisa Hom 2, Wenying Kang 2, Melanie Hayden Gephart 1, Larry Recht 7, Seema Nagpal 7, Reena Thomas 7, Chirag Patel 7, Gerald A. Rosenthal 2,3, Michael Iv 4, Michael Zhang 1, Johana C. Three patients with chronic dissection developed either pseudoaneurysm or true lumen compromise by expanded false lumen thrombi and required re-endografting.Research Paper EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial 121) dissection settings after mean follow-up of 14.0 ± 4.8 months in the AD group and 24.8 ± 5.9 months in the CD group. Intimomedial erosion of the distal end of the stent graft occurred in both acute (n = 6 18.9%) and chronic (n = 10 35.7% P =. 05), they were less prominent at the distal aorta in the CD aneurysm group. During follow-up, despite the proximal changes of stented true and adjacent false lumen diameter being significantly increased and decreased, respectively, in both acute and chronic settings ( P <. 221), but the complete regression rate of the thoracic false lumen down to the diaphragm level showed a tendency of propitious remodeling in the AD group (54.8% vs 30.8% P =. Complete thrombosis of the thoracic false lumen down to the diaphragm level was achieved in 80.6% of the patients in the AD group and 88.5% in the CD group without significant difference ( P =. 585) in a mean follow-up period of 24.1 ± 15.6 months. The cumulative survival rates of the two groups were similar (77.6% and 89.0% P =. The stent graft was successfully implanted in all patients (100%), with two surgical mortalities in the AD group and low perioperative morbidity (3.6%) of stroke and paraplegia.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |